The overall aim of CCIT is to significantly improve our ability to bridge the gap between discovery and clinical implementation in the field of cancer immunotherapy. CCIT has a focus on development of immunological treatment of cancer, and has a research profile based on equally weighted experimental and clinical projects with a tight interconnection. During the last few years we have carried out numerous clinical trials based on a direct translation of the discoveries from the laboratory. CCIT facilitates quick clinical implementation of new immunotherapies e.g. anti-CTLA4 therapy for melanoma which was implemented in the clinic only 3 weeks after publication of significant phase III data. And as the first and one of only 3 centres in Europe we established the advanced T-cell therapy for metastatic melanoma in the clinic. CCIT provides the infrastructure of certified clinical grade laboratory for preparation of therapeutic cellular products.
CCIT has a total of around 45 employees, including scientific and technical staff. We are focused on creating an international environment and have a long list of clinical and scientific collaborators illustrating the strong standing in field. Finally, CCIT contribute substantially to the education of next generation scientists and clinicians in the field.